Breaking News

Sirona Biochem, Wanbang Bio Enter SGLT2 Inhibitor Agreement

By Kristin Brooks | January 27, 2014

Wanbang gains an exclusive license to anti-diabetic treatment in China

Sirona Biochem Corp. has entered an agreement with Wanbang Biopharmaceuticals, providing Wanbang an exclusive license to develop and commercialize its anti-diabetic SGLT2 inhibitor in the People's Republic of China. Sirona will receive upfront and milestone payments of as much as $9.5 million, as well as royalties on sales.
 
Wanbang will be responsible for all funding, clinical development, regulatory requirements, manufacturing, sales and marketing of the SGLT2 inhibitor in China, and will share all data generated from its clinical studies, increasing the value of Sirona's SGLT2 inhibitor for licensing in the rest of the world.
 
"We are proud to work with Wanbang Biopharma in the continued development of our SGLT2 inhibitor as treatment for this global epidemic," said Neil Belenkie, chief executive officer of Sirona Biochem.

Related Contract Manufacturing:

blog comments powered by Disqus
  • Limiting APIs in Manufacturing Effluent

    Limiting APIs in Manufacturing Effluent

    Joan Tell, Robert Drinane, Bruce Naumann, Jessica Vestel, and Gregory Gagliano, Merck & Co., Inc.||June 2, 2016
    An approach for setting limits on pharmaceuticals discharged in manufacturing effluent

  • Successful Method Transfer of Solid Oral Dosage

    Successful Method Transfer of Solid Oral Dosage

    John Frankonis, Ropack Pharma Solutions||June 2, 2016
    The three steps outlined will help guide the process of completing a successful analytical method transfer

  • Who’s the Right Service Provider for You?

    Who’s the Right Service Provider for You?

    Raymond Peck, VxP Pharma Services||June 2, 2016
    Factors to consider when choosing between using one integrated CDMO or a series of smaller functional service providers